The push to contain spiraling health costs around the world could hamper the ability of drug makers to bring new medicines to market, two biopharmaceutical executives warned Wednesday.
Marijn Dekkers, chairman of German drug giant Bayer AG, sounded the alarm at a luncheon hosted by the Boston College Chief Executives’ Club of Boston, saying the global economic downturn has intensified pressure to restrict reimbursements for therapeutics.
Comments
Well they can take the same approach and decrease their worthless sales force and PR departments. Quite the contrary to their thinking efficiency frees up more dollars for proper research and innovation. Their beef is they want to go on making "me too" drugs or ones with very little improvement to what is already available.
yes, who needs new and better drugs. let some other country lead in this field.
Maybe China ...?
Other countries already do.
The fact is there are effective treatment for most ailments that afflict AMERICANS, and many of them are vastly over-prescribed. Many new drugs today are just variations of popular medications seeking to grab market share. Meanwhile research into diseases in Africe that afflict millions are not even being pursued.